Table 5.

Adverse events reported in association with tocilizumab and abatacept use 4,104,106,109,110

Adverse event categories	Tocilizumab	Abatacept
Musculoskeletal	Arthritis flare, fracture, septic arthritis, hip dislocation MAS	Arthritis flare, arthralgia, foot deformity
Haematological	Neutropenia, leucopenia	–
Gastrointestinal	Gastrointestinal bleeding, increase in transaminases, diarrhoea	Vomiting
Cardiorespiratory	Pneumothorax, cardiac failure, pulmonary veno-occlusive disease	–
Infectious	Infectious mononucleosis, nasopharyngitis, URTI, gastroenteritis, varicella/herpes zoster infections, pneumonia	Nasopharyngitis, URTI, dengue fever, erysipelas, gastroenteritis, herpes zoster, bacterial meningitis, pyelonephritis, varicella infection
Opthalmological	–	Uveitis
Immunological and/or autoimmune	Anaphylactic reaction, mild-to-moderate infusion reactions, anti-tocilizumab antibodies, angioedema, urticaria	Anti-abatacept antibodies, multiple sclerosis*, acute infusion reactions†
Neurological	Headaches	–
Dermatological	Chronic panniculitis	–
Oncological	–	Acute lymphoblastic leukaemia‡, benign neoplasms§
Other	Elevated total cholesterol, testicular torsion	Pyrexia, ovarian cyst

Abbreviation is as follows: MAS, macrophage activation syndrome, URTI, upper respiratory tract infection.

^*Developed after 19 months of abatacept treatment.

^†Dizziness, nausea, vomiting, headache, hypersensitivity, rhinitis.

^‡Diagnosed at day 89 of the open-label lead-in phase and thought to have been initially misdiagnosed as juvenile idiopathic arthritis.

^§Four benign neoplasms were reported but no malignancies.